Narcan nasal spray (naloxone hydrochloride), a drug indicated for the emergency treatment of a known or suspected opioid overdose, has received FDA approval for a new 2mg dose.
The new 2mg dose is indicated for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. Narcan nasal spray was originally approved in November 2015 in a 4mg dose
Narcan nasal spray is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. It reverses the effects of opioids, including respiratory depression, sedation, and hypotension, but it is not a substitute for emergency medical care. Always seek emergency medical assistance in the event of a suspected, potentially life-threatening opioid emergency after administration of the first dose of Narcan nasal spray.
For more information on this new dose, read Adapt Pharma’s press release.